TENKU
Citius Oncology Inc. - Units (1 Ord & 1 Rts)

0
Loading...
Loading...
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Citius Oncology Inc. - Units (1 Ord & 1 Rts)?
What is the 52-week high for Citius Oncology Inc. - Units (1 Ord & 1 Rts)?
What is the 52-week low for Citius Oncology Inc. - Units (1 Ord & 1 Rts)?
What is Citius Oncology Inc. - Units (1 Ord & 1 Rts) stock price today?
What was Citius Oncology Inc. - Units (1 Ord & 1 Rts) stock price yesterday?
What is the PE ratio of Citius Oncology Inc. - Units (1 Ord & 1 Rts)?
What is the Price-to-Book ratio of Citius Oncology Inc. - Units (1 Ord & 1 Rts)?
What is the 50-day moving average of Citius Oncology Inc. - Units (1 Ord & 1 Rts)?

Latest TENKU News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.